E-mail| Contact Us| Volunteer| Make A Gift| En Español| Employees

  • Take Control of your Smoking History
  • World-class cancer care made LG Health his top destination

Learn More

Ann B. Barshinger Cancer Institute

Read the Oncology Program Annual Report 2013
Oncology Clinical Trials

Oncology Clinical Trials

New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.

The Ann B. Barshinger Cancer Institute participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.


Current oncology treatment trials open for participation:

Site Study Title

Alliance A071102


Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MBMT Promoter Hypermethylation.




PALLAS: Palbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer



A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer.

In conjunction with Penn


Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer




A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer




Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

BMS CA 209-602


An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma




A phase iii, open-label, randomized study to investigate the efficacy and safety of atezolizumab(antipd l1 antibody) compared with best supportive care following adjuvant cisplatin based chemotherapy in pd l1selected patients with completely resected stage ib-iiia non-small cell lung cancer

BMS  CA209-9L


A Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-small Cell Lung Cancer


Step 0 is closed


Molecular Analysis for Therapy Choice (MATCH)

If you have any questions contact oncology research at 717-544-0511

Updated 7/19/2017


Find A Doctor
Advanced Search
Call 1-888-LGH-INFO

Learn More


Contact Us:

1-888-LGH-INFO (544-4636) Have a question?
Follow us online.